Quick charity verification for Alzheimers Drug Discovery Foundation (EIN: 201082179)
Verdict: Alzheimers Drug Discovery Foundation appears trustworthy
90/100Mission Score
$56.4MRevenue
$299.4MAssets
2Red Flags
4Strengths
Red Flags
Inconsistent revenue generation, with significant fluctuations year-over-year (e.g., $254M in 2022 vs. $37.7M in 2023).
Expenses exceeding revenue in multiple periods (e.g., 2023, 2019, 2017), indicating reliance on reserves or investment income.
Strengths
Strong program spending ratio, with 85% of expenses dedicated to programs in 2023.
Significant and consistent growth in assets, from $19.3M in 2014 to $324.1M in 2023, indicating robust financial health.
Consistent reporting of 0% officer compensation across all filings, suggesting efficient use of funds or unique compensation structure.
Substantial financial reserves, with assets significantly outweighing liabilities (e.g., $324.1M assets vs. $64.1M liabilities in 2023).
Spending Breakdown
How Alzheimers Drug Discovery Foundation allocates its funds across programs, administration, and fundraising.
85%
Program Spending
Healthy — majority goes to mission
10%
Admin Costs
Reasonable — admin costs in check
5%
Fundraising
Within typical range
How to read this: Well-run charities typically spend 75% or more on programs, keep admin under 25%, and fundraising under 15%. A high program ratio means more of every dollar goes directly to the mission.
How to Interpret This Report
What Red Flags Mean
Red flags are potential warning signs identified by AI analysis of IRS 990 filings. They may indicate issues like declining revenue, high executive pay relative to program spending, lack of transparency, or governance concerns. A single red flag does not necessarily mean an organization is untrustworthy, but multiple flags warrant further investigation before donating.
What Mission Score Measures
The Mission Score (0-100) evaluates how effectively a nonprofit fulfills its stated purpose. It combines multiple factors: program spending efficiency (how much goes to programs vs. overhead), financial health and sustainability, governance quality, transparency in reporting, and consistency of operations over time. A score of 70+ indicates strong alignment with the organization’s mission.
Using This Data for Donation Decisions
Use this report as one input in your decision. Look at the overall Mission Score for a quick assessment, review red flags and strengths for specific concerns, check the spending breakdown to see where money goes, and compare executive compensation to the organization’s size. Consider viewing the full transparency report for deeper analysis, and always verify tax-exempt status with the IRS before making large donations.
Frequently Asked Questions about Alzheimers Drug Discovery Foundation
Is Alzheimers Drug Discovery Foundation a legitimate charity?
Based on AI analysis of IRS 990 filings, Alzheimers Drug Discovery Foundation (EIN: 201082179) appears trustworthy. Mission Score: 90/100. 2 red flags identified, 4 strengths noted.
Is Alzheimers Drug Discovery Foundation a good charity to donate to?
Alzheimers Drug Discovery Foundation has a Mission Score of 90/100. Revenue: $56.4M. Assets: $299.4M. Review the full transparency report for detailed spending breakdown and executive compensation analysis.
What is the EIN for Alzheimers Drug Discovery Foundation?
The Employer Identification Number (EIN) for Alzheimers Drug Discovery Foundation is 201082179. This is the unique tax ID assigned by the IRS.
What is a Mission Score?
The Mission Score is a 0-100 rating that measures how effectively a nonprofit fulfills its stated mission. It factors in program spending efficiency, financial transparency, governance practices, and outcome reporting. Scores above 70 indicate strong mission alignment, 40-69 suggest mixed performance, and below 40 signals potential concerns.
How does Alzheimers Drug Discovery Foundation spend its money?
Alzheimers Drug Discovery Foundation allocates 85% to programs, 10% to administration, and 5% to fundraising. Healthy nonprofits typically spend 75%+ on programs.
How can I verify Alzheimers Drug Discovery Foundation's tax-exempt status?
You can verify Alzheimers Drug Discovery Foundation's tax-exempt status using EIN 201082179 on the IRS Tax Exempt Organization Search (TEOS) at apps.irs.gov/app/eos. You can also request copies of their Form 990 directly from the organization, as they are required by law to provide them upon request.
AI Transparency Report
The Alzheimers Drug Discovery Foundation (ADDF) demonstrates a strong commitment to its program services, with a significant portion of its expenses directed towards its mission. For instance, in 2023, 85% of its total expenses were allocated to program services, indicating efficient use of donor funds for its core activities. The organization has also shown substantial growth in assets, from $19.3 million in 2014 to over $324 million in 2023, suggesting robust financial management and fundraising success. However, there have been periods where expenses exceeded revenue, such as in 2023 where expenses were $61.9 million against $37.7 million in revenue, and in 2019 where expenses were $32.4 million against $22.7 million in revenue. This indicates reliance on prior year surpluses or investment income to cover operational costs in some periods.
ADDF's financial health appears generally strong, supported by substantial assets and a history of significant revenue generation, particularly the $254 million in revenue reported in 2022. The consistent reporting of 0% officer compensation across all available filings is a notable aspect of its transparency and financial practices, suggesting that executive leadership is not directly compensated through the organization's funds, or that compensation is reported differently. This practice, if accurately reflecting no direct compensation, could be seen as a positive indicator of resource allocation towards the mission.
Overall, ADDF exhibits a healthy financial position with a clear focus on program spending. While there are fluctuations in annual revenue and expenses, the long-term trend shows significant asset growth and a consistent dedication to its mission. The absence of reported officer compensation is a unique and positive transparency feature, contributing to a favorable view of its financial stewardship.